Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy / 医学前沿
Frontiers of Medicine
;
(4): 307-321, 2022.
Artículo
en Inglés
| WPRIM
| ID: wpr-939881
ABSTRACT
The discovery of immune checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4, has played an important role in the development of cancer immunotherapy. However, immune-related adverse events often occur because of the enhanced immune response enabled by these agents. Antibiotics are widely applied in clinical treatment, and they are inevitably used in combination with immune checkpoint inhibitors. Clinical practice has revealed that antibiotics can weaken the therapeutic response to immune checkpoint inhibitors. Studies have shown that the gut microbiota is essential for the interaction between immune checkpoint inhibitors and antibiotics, although the exact mechanisms remain unclear. This review focuses on the interactions between immune checkpoint inhibitors and antibiotics, with an in-depth discussion about the mechanisms and therapeutic potential of modulating gut microbiota, as well as other new combination strategies.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Receptor de Muerte Celular Programada 1
/
Inhibidores de Puntos de Control Inmunológico
/
Inmunoterapia
/
Antibacterianos
/
Neoplasias
Tipo de estudio:
Investigación cualitativa
Límite:
Humanos
Idioma:
Inglés
Revista:
Frontiers of Medicine
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS